BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 3, 2011 7:00 AM UTC

Amarin Corp. plc (NASDAQ:AMRN) was off $1.43 (13%) to $9.20 last week. The company submitted an NDA to FDA for AMR101 to treat hypertriglyceridemia in patients with triglyceride levels of 500 mg/dL or greater.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was off $0.40 (10%) to $3.64 last week after submitting an NDA to FDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension. The company requested Priority Review...